financetom
Business
financetom
/
Business
/
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
Oct 15, 2025 7:02 AM

SciSparc Ltd. ( SPRC ) traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures Inc. (TSXV:MIZA), a publicly traded firm on Canada's TSX Venture Exchange

The Tel Aviv-based pharmaceutical company develops treatments for central nervous system and rare disorders. It finalized its deal with Miza III on Oct. 9

The transaction values SciSparc's ( SPRC ) drug assets and its majority interest in SciSparc Nutraceuticals Inc. at about $11.6 million, while Miza is valued at roughly $3.3 million, including its $1 million cash position.

Under the agreement, SciSparc ( SPRC ) will receive 63.3 million common shares of Miza and up to 48 million contingent rights tied to milestone achievements.

The company will hold between 75% and 84% of Miza following the completion of the transaction. Miza will then rebrand as NeuroThera Labs Inc. and operate in both pharmaceutical and nutritional supplement markets.

Also Read: SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

SciSparc ( SPRC ) or a third party will provide up to CAD 1 million (about $716,000) in capital through a two-year, 7% convertible note, allowing conversion into as many as four million Miza shares at CAD 0.25 per share. Miza will also issue four million warrants exercisable at the same price for a period of five years.

The deal supports SciSparc's ( SPRC ) plan to broaden its presence in life sciences and increase shareholder value. The transaction, approved conditionally by the TSX Venture Exchange, is expected to close on or around October 22.

Earlier this year, SciSparc ( SPRC ) shifted focus after it called off merger discussions with AutoMax Motors, a move that redirected its strategy toward biotechnology and therapeutics.

Price Action: SciSparc ( SPRC ) stock is trading at around $3.82 per share, a 10.72% increase, at the last check on Wednesday.

Read Next:

Astera Labs Jumps Over 5% Pre‑Market Amid New Arm Partnership

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Caterpillar, Hunt Energy Collaborate to Provide Power Services for Data Centers
Caterpillar, Hunt Energy Collaborate to Provide Power Services for Data Centers
Aug 21, 2025
09:27 AM EDT, 08/21/2025 (MT Newswires) -- Caterpillar ( CAT ) and Hunt Energy said Thursday that they have formed a collaboration to provide power services for data centers. Financial details of the collaboration were not disclosed. Caterpillar ( CAT ) will use its portfolio of power services and will provide monitoring and servicing products, the companies said. Hunt will...
ADB to provide $410 million package for Barrick-run Pakistan mine, sources say
ADB to provide $410 million package for Barrick-run Pakistan mine, sources say
Aug 21, 2025
* ADB to provide $410 million package for copper-gold mine * Package includes a $300 million in loans to Barrick Gold ( B ) (Updates throughout) By Saeed Shah and Ariba Shahid ISLAMABAD, Aug 21 (Reuters) - The Asian Development Bank will provide a $410 million financing package to help develop Pakistan's Reko Diq copper mine, one of the world's...
AbbVie Says 2nd Phase 3 Trial Evaluating Upadacitinib for Alopecia Areata Met Primary Endpoint
AbbVie Says 2nd Phase 3 Trial Evaluating Upadacitinib for Alopecia Areata Met Primary Endpoint
Aug 21, 2025
09:29 AM EDT, 08/21/2025 (MT Newswires) -- AbbVie ( ABBV ) said Thursday that topline results from the second of two pivotal studies of a phase 3 trial showed that upadacitinib improved scalp and non-scalp hair regrowth in adult and adolescent patients with severe alopecia areata. The study achieved the primary endpoint with 45.2% and 55% of patients treated with...
Crinetics Pharmaceuticals Gets FDA Orphan Drug Designation for Atumelnant
Crinetics Pharmaceuticals Gets FDA Orphan Drug Designation for Atumelnant
Aug 21, 2025
09:25 AM EDT, 08/21/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) said Thursday the US Food and Drug Administration has granted orphan drug designation to atumelnant, its oral drug candidate for classic congenital adrenal hyperplasia. The company said the designation follows phase 2 trial results that indicated reductions in key biomarkers and clinical symptoms in adults with the condition....
Copyright 2023-2026 - www.financetom.com All Rights Reserved